Evidence map›Paper›PMID 33088650›Full record

Article3 Biotech2020

MicroRNA-199a-5p suppresses the cell growth of colorectal cancer by targeting oncogene Caprin1.

Xiangyang Yu, Yanfang He, Yan Wang, Yajuan Tang, Yanjuan Guo, Jinling Yuan, Jinghe Bai, Tao Yao, Xiongzhi Wu

RetractedOpen access · greenAbstract readRetracted Publication
In one paragraph

Article in 3 Biotech, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Chronic Pesticide Exposure in Farm Workers Is Associated with the Epigenetic Modulation of hsa-miR-199a-5p.International journal of environmental research and public health · 2022
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiangyang YuKey Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, No.22 Qi-Xiang-Tai Road, Tianjin, 300000 People's Republic of China.
Yanfang HeDepartment of Obstetrics and Gynecology, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000 People's Republic of China.
Yan WangDepartment of Obstetrics and Gynecology, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000 People's Republic of China.
Yajuan TangDepartment of Obstetrics and Gynecology, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000 People's Republic of China.
Yanjuan GuoDepartment of Obstetrics and Gynecology, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000 People's Republic of China.
Jinling YuanDepartment of Obstetrics and Gynecology, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000 People's Republic of China.
Jinghe BaiDepartment of Obstetrics and Gynecology, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000 People's Republic of China.
Tao YaoDepartment of Obstetrics and Gynecology, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000 People's Republic of China.
Xiongzhi WuKey Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, No.22 Qi-Xiang-Tai Road, Tianjin, 300000 People's Republic of China.ORCID 0000-0001-5055-2864
North China University of Science and Technology · CNTianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs-199a-5p (miR-199a-5p) plays critical regulatory roles in various types of human cancers. However, the biological function and regulatory mechanisms of miR-199a-5p in colorectal cancer (CRC) remain unclear. The aim of this study was to investigate the role of miR-199a-5p in CRC and possible mechanisms of its action. The expression of miR-199a-5p in CRC tumor tissues was validated using quantitative real-time PCR (qRT-PCR). The effects of miR-199a-5p on cell proliferation and apoptosis were evaluated in vitro. Then, the association of miR-199a-5p and its downstream target was investigated in both cell line and clinical specimens. Furthermore, gain- and loss-of-function studies of cytoplasmic activation/proliferation-associated protein-1 (Caprin1) were performed to assess whether the suppressive effect of on CRC cells were via targeting Caprin1. Using a microarray platform, we focused on miR-199a-5p for further research, which was one of the most markedly downregulated miRNAs in CRC tumor tissues. Functionally, the overexpression of miR-199a-5p inhibited proliferation and induced apoptosis in both HTC116 and SW480 cells. Furthermore, cytoplasmic activation/proliferation-associated protein-1 (Caprin1), a well-known oncogene, was directly targeted by miR-199a-5p. It was also observed that Caprin1 was upregulated, and inversely correlated with miR-199a-5p levels in CRC tissues. Further investigations revealed that knockdown of Caprin1 by siRNA has similar role with miR-199a-5p overexpression in CRC cells, suggesting the oncogenic role of Caprin1 in CRC. In the contrast, we found that overexpression of Caprin1 reversed the suppressive effects of miR-199a-5p on CRC cells. Collectively, our study suggests that miR-199a-5p/Caprin1 axis may serve as potential therapeutic targets for the treatment of CRC.

Indexed as

ApoptosisCaprin1Colorectal cancerMicroRNA-199a-5pProliferationTumor suppressor

Identifiers

PMID33088650
PMCPMC7519927
OpenAlexW3088346623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.